Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 11, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2027 | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Trial Milestone | Phase 2 |
| February 15, 2028 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Trial Milestone | Phase 1 |
| February 15, 2029 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | Trial Milestone | Phase 1/Phase 2 |
| January 15, 2030 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Trial Milestone | Phase 1 |
Track ALLO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ALLO in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.